Key result
Coronary sinus neuropeptide Y levels ≥130 pg/mL were associated with event-free survival (death, cardiac transplant, or left ventricular assist device) (HR 9.5; 95% CI, 2.92-30.5; P<.001).
Why the study?
Chronic heart failure is linked to increased sympathetic drive and may raise neuropeptide Y expression, but whether myocardial levels correlate with outcomes was unknown.
Are elevated coronary sinus neuropeptide Y levels associated with adverse outcomes in patients with stable chronic heart failure undergoing CRT?
Population
105 stable heart failure patients undergoing elective CRT implantation
Comparison
Coronary sinus NPY levels
Design
Single-center prospective observational cohort study
Authors
Loading...
High NPY may flag high-risk HF patients for monitoring; leaves open incremental value over existing models.
Cohort (n=105)
No
Are elevated coronary sinus neuropeptide Y levels associated with adverse outcomes in patients with stable chronic heart failure undergoing CRT?
Hazard Ratio: 9.5 (95% CI 2.92–30.5)
p-value: p=< .001
Elevated coronary sinus neuropeptide Y levels (≥ 130 pg/mL) are strongly associated with adverse outcomes in patients with stable chronic heart failure undergoing CRT.
Ajijola et al. (2019) conducted a cohort in Stable chronic heart failure (n=105). Coronary sinus neuropeptide Y levels ≥ 130 pg/mL vs. Coronary sinus neuropeptide Y levels < 130 pg/mL was evaluated on Event-free (death, cardiac transplant, or left ventricular assist device) survival (HR 9.5, 95% CI 2.92-30.5, p=< .001). Coronary sinus neuropeptide Y levels ≥130 pg/mL were associated with event-free survival (death, cardiac transplant, or left ventricular assist device) (HR 9.5; 95% CI, 2.92-30.5; P<.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: